AbbVie Inc. (ABBV)
We Said These 4 Dividend Aristocrats Could Soar. Here's How They Did, Plus 3 New Picks.
About a year ago, 24/7 Wall St. flagged four overlooked Dividend Aristocrats as stealth growth plays, arguing that boring income names carried real upside if the market ever noticed.
3 Beaten-Down Healthcare Stocks to Buy in August
Year to date, the healthcare sector finds itself in the middle of the S&P 500's pack.
ABBV Stock Dips 4% Despite Robust Q2: Buy the Dip or Stay Cautious?
ABBV falls after cutting its 2026 EPS outlook to reflect the Apogee deal, despite strong Q2 results, higher revenue guidance and growth from key medicines.
Is It Worth Investing in AbbVie (ABBV) Based on Wall Street's Bullish Views?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Prediction: AbbVie Will End The Year at This Price
I'm going to put our year-end call on the table before anything else. Our AbbVie (NYSE:ABBV | ABBV Price Prediction) year-end verdict is a buy, and our proprietary model sees more room to run despite the stock already sitting near record highs.
ABBV Q2 Earnings Call Balances Growth With Apogee Dilution
AbbVie raises 2026 revenue guidance on Skyrizi, Rinvoq and neuroscience growth, while the Apogee deal trims EPS guidance and lifts R&D spending.
AbbVie Inc. (ABBV) Q2 2026 Earnings Call Transcript
AbbVie Inc. (ABBV) Q2 2026 Earnings Call Transcript
ABBV Beats on Q2 Earnings & Sales, Cuts '26 EPS View, Stock Down
AbbVie tops Q2 earnings and revenue estimates on strong immunology drug sales, but a lower 2026 EPS outlook tied to the Apogee deal weighs on shares.
Pre-Market Trading Up in Final Session of the Week
Despite some mid-week turbulence, we're trading fairly even with where we were as of mid-day Monday.
AbbVie Q2 Earnings Call Highlights
AbbVie NYSE: ABBV reported second-quarter 2026 results that exceeded its expectations, supported by double-digit growth in its immunology and neuroscience businesses, and raised its full-year revenue outlook by $300 million.
AbbVie (ABBV) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for AbbVie (ABBV) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
AbbVie (ABBV) Q2 Earnings and Revenues Beat Estimates
AbbVie (ABBV) came out with quarterly earnings of $3.65 per share, beating the Zacks Consensus Estimate of $3.64 per share. This compares to earnings of $2.97 per share a year ago.
